SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting Life Science Investing
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update Life Science Investing
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting Life Science Investing
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements Life Science Investing
PTC Teams with NVIDIA to Unite Design and Robotics Simulation by Connecting Onshape to NVIDIA Isaac Sim Life Science Investing
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Life Science Investing
